PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 16374778-6 2006 PMA, which mimics diacylglycerol (DAG) as an activator of cPKC, novel-PKC (nPKC), and non-PKC DAG-driven molecule(s), produced a dose-dependent dual effect on phagocytosis by CR3/MAC-1 and SRAI/II, i.e., augmentation at low concentrations and inhibition at high concentrations. Diglycerides 18-32 teratocarcinoma-derived growth factor 1 pseudogene 3 Homo sapiens 175-178 16374778-6 2006 PMA, which mimics diacylglycerol (DAG) as an activator of cPKC, novel-PKC (nPKC), and non-PKC DAG-driven molecule(s), produced a dose-dependent dual effect on phagocytosis by CR3/MAC-1 and SRAI/II, i.e., augmentation at low concentrations and inhibition at high concentrations. Diglycerides 34-37 teratocarcinoma-derived growth factor 1 pseudogene 3 Homo sapiens 175-178 16374778-6 2006 PMA, which mimics diacylglycerol (DAG) as an activator of cPKC, novel-PKC (nPKC), and non-PKC DAG-driven molecule(s), produced a dose-dependent dual effect on phagocytosis by CR3/MAC-1 and SRAI/II, i.e., augmentation at low concentrations and inhibition at high concentrations. Diglycerides 94-97 teratocarcinoma-derived growth factor 1 pseudogene 3 Homo sapiens 175-178 16374778-7 2006 Inhibition of phagocytosis by CR3/MAC-1 was enhanced by combining inhibiting concentrations of PMA with PKC inhibitors Go-6976 or Ro-318220, suggesting inhibition by PMA/DAG-driven non-PKC molecule(s). Diglycerides 170-173 teratocarcinoma-derived growth factor 1 pseudogene 3 Homo sapiens 30-33 16374778-11 2006 The two differ, however, in that non-PKC DAG-driven molecule(s) inhibit CR3/MAC-1-mediated phagocytosis, whereas nPKC inhibit SRAI/II-mediated phagocytosis. Diglycerides 41-44 teratocarcinoma-derived growth factor 1 pseudogene 3 Homo sapiens 72-75